Natural Product (NP) Details
| General Information of the NP (ID: NP0587) | |||||
|---|---|---|---|---|---|
| Name |
Glatiramer acetate
|
||||
| Synonyms |
Glatiramer acetate; 147245-92-9; Copaxone; Copolymer 1; Copolymer-1; Protiramer; Glatopa; COP-1; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; 5M691HL4BO; DTXSID30163637; C9H11NO3.C6H14N2O2.; AM84438; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt); AC-28732; L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); AB0110033; Y0429; Q418274; acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid
Click to Show/Hide
|
||||
| Species Origin | Homo sapiens ... | Click to Show/Hide | |||
| Homo sapiens | |||||
| Disease | Multiple sclerosis [ICD-11: 8A40] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C25H45N5O13
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N
|
||||
| InChI |
1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
|
||||
| InChIKey |
FHEAIOHRHQGZPC-KIWGSFCNSA-N
|
||||
| CAS Number |
CAS 147245-92-9
|
||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Minocycline | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IL5 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | EAE was induced in C57/BL6 mice by using 50 Ag of the immunogenic myelin oligodendrocyte glycoprotein (MOG) peptide. | |||||
| Experimental
Result(s) |
This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination. | |||||
| Atorvastatin | Cardiovascular disease | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL12A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Female (PL/J * SJL/J)mice were immunized with MBP Ac1-11 (100 ug) to establish the animal model. | |||||
| Experimental
Result(s) |
Monocytes treated with the combination of suboptimal doses of atorvastatin and GA secreted an antiinflammatory type II cytokine pattern and, when used as APCs, promoted Th2 differentiation of naive myelin-specific T cells. | |||||
